Gain 30% Efficiency

Choosing a Centralized Monitoring Platform

Six Questions to Ask 

Selecting a centralized monitoring platform is about more than comparing features. It’s about choosing how your clinical operations team will identify emerging risks, protect participants and maintain effective oversight throughout the clinical trial. 

The right system should help you turn complex, accumulating trial data into clear, actionable insight. It should also support a monitoring strategy that is proportionate to the risks of your study and sustainable across the trial lifecycle. 

If you are assessing centralized monitoring software, these six questions can help you compare solutions with greater confidence. 

Does it prioritize signal quality?

A platform may generate hundreds of alerts, but that does not necessarily mean it is helping your team manage risk effectively. An isolated outlier is not always a meaningful signal, and excessive false positives can quickly overwhelm reviewers. 

Look for analytics that help users assess: 

  • The context surrounding a signal. 
  • Its potential significance. 
  • The possible impact on participant safety, data integrity or trial reliability. 
  • Whether the finding is an isolated event or part of a wider trend.
 

Effective centralized monitoring should focus attention where it is most needed, not simply increase the volume of alerts.

Can you configure it for your study?

“AI-powered” is not, by itself, a meaningful evaluation criterion. The more important question is whether the platform can reflect the design, risks and operational context of your specific study. 

Check whether users can configure KRIs, KPIs and QTLs according to factors such as: 

  • The protocol and visit schedule. 
  • The therapeutic area. 
  • The study population. 
  • The study-specific risk profile. 
  • The data sources available for review. 
 

A useful platform should adapt to your monitoring strategy rather than forcing your study into a generic framework. It should provide a practical starting point while allowing your team to define new indicators, visualizations and thresholds when requirements change. OPRA, for example, supports configurable KRIs, KPIs and QTLs for different studies and therapeutic areas. 

Can reviewers investigate signals at subject level?

A study-level dashboard is useful for identifying broad patterns, but it is rarely enough to support effective follow-up. Clinical operations teams need to understand what is driving a trend and where action may be required. 

Ask whether reviewers can move from a study-level signal to the relevant: 

  • Country or site. 
  • Subject. 
  • Visit. 
  • Data point. 
  • Source-system record. 

This drill-down should be available without a separate data request or manual spreadsheet exercise. The faster reviewers can move from a pattern to its underlying context, the more efficiently they can determine whether the issue requires escalation, investigation or no further action. 

Does it support the full RBQM workflow?

Centralized monitoring should not end when a signal appears on a dashboard. A complete risk-based quality management process requires teams to assess the finding, decide what it means, assign ownership and document the outcome. 

Look for workflows that connect: 

  • Risk identification. 
  • Signal assessment. 
  • Ownership and escalation. 
  • Corrective and preventive action. 
  • Follow-up and resolution. 
  • Inspection-ready documentation. 

This connection matters because risk management is an ongoing process rather than a series of disconnected reviews. When monitoring findings, decisions and actions are managed in one environment, teams have a clearer view of what happened, why it happened and whether the issue was resolved. 

OPRA combines centralized monitoring with risk assessment, risk management and action tracking, helping sponsors and CROs manage risks and controls within a connected RBQM framework. 

Does it support regulatory expectations?

A centralized monitoring platform should support a proportionate, study-specific monitoring strategy focused on critical data and processes. It should help your organization demonstrate how risks were identified, assessed, monitored and addressed. 

ICH E6(R3) describes centralized monitoring as the timely evaluation of accumulated data by appropriately qualified and trained sponsor personnel. It also recognizes that centralized monitoring may complement, reduce or replace some site monitoring when appropriate. 

When evaluating a system, consider how it supports: 

  • The monitoring plan. 
  • Study-level risk assessments. 
  • Critical-to-quality factors. 
  • KRI and QTL management. 
  • Documented review decisions. 
  • Oversight responsibilities. 
  • Evidence of follow-up and issue resolution.
 

The platform should make your operating model easier to apply and easier to explain during an inspection. Technology cannot replace a sound monitoring strategy, but it should provide the structure and evidence needed to implement that strategy consistently. 

Can it demonstrate data lineage and scale?

A successful case study from one large, high-enrolment trial does not automatically demonstrate that a platform is suitable for your study. Before making a decision, ask vendors to show how the system performs across different study designs, data environments and operational conditions. 

Request a realistic demonstration of how the platform handles: 

  • Data refreshes and source-system changes. 
  • User permissions and role-based access. 
  • Changes to thresholds, algorithms or configurations. 
  • Audit trails and decision history. 
  • Different study phases and populations. 
  • Low-volume, complex or high-risk studies. 
  • Changing enrolment levels and data volumes. 
 

You should be able to see how data moves from source systems into the platform, how changes are controlled and how users can reconstruct the history of a decision. End-to-end data lineage, controlled change management and complete audit trails are essential for reliable oversight and inspection readiness. 

Use realistic scenarios to compare vendors 

The strongest centralized monitoring platforms help clinical operations teams see what is changing, understand why it matters and take proportionate action. 

At TRI, this is the standard applied to OPRA. The platform is designed to turn fragmented trial data into a contextual view of study health, supporting earlier and better-informed RBQM decisions. Its centralized monitoring capabilities also provide tools for recording comments and actions linked to studies, sites and data, with information available for reporting and export. 

To assess whether a platform is right for your organization, ask every vendor to demonstrate the six capabilities above using a realistic study scenario. The most useful demonstration will show not only how the system detects a signal, but how your team would investigate it, assign follow-up, document the decision and confirm resolution. 

Explore OPRA Central Monitoring to see how TRI applies centralized monitoring in practice.